Fermented ingredients maker Amyris extends production contract with ADL

US-based producer of fermented ingredients Amyris has extended its production contract with Antibióticos de León (ADL).

Under the contract, Amyris will work collaboratively with ADL to offer additional manufacturing capability to its partners.

Amyris president and CEO John Melo said: “It’s great to be able to rely on ADL to respond quickly, just as we did when we took an active ingredient in skincare from development to commercial scale in record time.

“Low-cost, high purity and predictability are what our customers have come to depend on Amyris for.”

Amyris leverages advanced science and technology, including machine-learning and robotics to programme yeast to create targeted molecules for use in the beauty, flavours and fragrances, health and wellness, and cosmetics ingredients markets.

The company currently manufactures and commercialises 15 products through supply agreements across a range of business segments.

ADL Biopharma CEO Pilar de la Huerta said: “With the extension of the original collaboration signed in January, we are increasing our commitment and strengthening our relationship with one of our key customers.

“With this increase, not only in the amount but also in the number of products manufactured for Amyris in ADL facilities, Amyris and ADL reinforce their mutual support commitment to a successful long-term relationship.”

ADL Biopharma develops and produces fermentation process-based projects at its fermentation facility in Southern Europe.

The company operates in three separate business lines serving markets across Europe and the US.